Amyotrophic lateral sclerosis (ALS) is a devastating, uniformly lethal progressive degenerative disorder of motor neurons that overlaps with frontotemporal lobar degeneration (FTLD) clinically, morphologically, and genetically. Although many distinct mutations in various genes are known to cause amyotrophic lateral sclerosis, it remains poorly understood how they selectively impact motor neuron biology and whether they converge on common pathways to cause neuronal degeneration. Many of the gene mutations are in proteins that share similar functions. They can be grouped into those associated with cell axon dynamics and those associated with cellular phagocytic machinery, namely protein aggregation and metabolism, apoptosis, and intracellular nucleic acid transport. Analysis of pathways implicated by mutant ALS genes has provided new insights into the pathogenesis of both familial forms of ALS (fALS) and sporadic forms (sALS), although, regrettably, this has not yet yielded definitive treatments. Many genes play an important role, with TARDBP, SQSTM1, VCP, FUS, TBK1, CHCHD10, and most importantly, C9orf72 being critical genetic players in these neurological disorders. In this mini-review, we will focus on the molecular mechanisms of these two diseases.

Department of Pathology 1st Faculty of Medicine Charles University and General University Hospital 14059 Prague Czech Republic

Department of Pathology 3rd Faculty of Medicine Charles University and University Hospital Kralovske Vinohrady 14059 Prague Czech Republic

Department of Pathology and Molecular Medicine 3rd Faculty of Medicine Charles University and Thomayer University Hospital 14059 Prague Czech Republic

See more in PubMed

Kang S.H., Li Y., Fukaya M., Lorenzini I., Cleveland D.W., Ostrow L.W., Rothstein J.D., Bergles D.E. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 2013;5:571–579. doi: 10.1038/nn.3357. PubMed DOI PMC

Al-Chalabi A., Andersen P.M., Chandran S., Chio A., Corcia P., Couratier P., Danielsson O., De Carvaiho M., Desnuelle C., Grehl T., et al. July 2017 ENCALS statement on edaravone. Amyotroph Lateral Scler Front. Degener. 2017;18:471–474. doi: 10.1080/21678421.2017.1369125. PubMed DOI

Rowland L.P., Shneider N.A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2001;22:1688–1700. doi: 10.1056/NEJM200105313442207. PubMed DOI

Chiò A., Moglia C., Canosa A., Manera U., D’Ovidio F., Vasta R., Grassano M., Brunetti M., Barberis M., Corrado L., et al. ALS phenotype is influenced by age, sex, and genetics: A population-based study. Neurology. 2020;8:e802–e810. doi: 10.1212/WNL.0000000000008869. PubMed DOI

Andersen P.M., Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: What do we really know? Nat. Rev. Neurol. 2011;11:603–615. doi: 10.1038/nrneurol.2011.150. PubMed DOI

Yrne S., Walsh C., Lynch C., Bede P., Elamin M., Kenna K., McLaughlin R., Hardiman O. Rate of familial amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry. 2011;6:623–627. PubMed

Deivasigamani S., Verma H.K., Ueda R., Ratnaparkhi A., Ratnaparkhi G.S. A genetic screen identifies Tor as an interactor of VAPB in a Drosophila model of amyotrophic lateral sclerosis. Biol. Open. 2014;11:1127–1138. doi: 10.1242/bio.201410066. PubMed DOI PMC

Hardiman O., Van den Berg L.H., Kiernan M.C. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011;11:639–649. doi: 10.1038/nrneurol.2011.153. PubMed DOI

Kiernan M.C., Vucic S., Cheah B.C., Turner M.R., Eisen A., Hardiman O., Burrell J.R., Zoing M.C. Amyotrophic lateral sclerosis. Lancet. 2011;377:942–955. doi: 10.1016/S0140-6736(10)61156-7. PubMed DOI

Nguyen H.P., Van Broeckhoven C., Van der Zee J. ALS Genes in the Genomic Era and their Implications for FTD. Trends Genet. 2018;34:404–423. doi: 10.1016/j.tig.2018.03.001. PubMed DOI

Ling S.C., Polymenidou M., Cleveland D.W. Converging mechanisms in ALS and FTD: Disrupted RNA and protein homeostasis. Neuron. 2013;79:416–438. doi: 10.1016/j.neuron.2013.07.033. PubMed DOI PMC

Hodges J.R., Davies R., Xuereb J., Kril J., Halliday G. Survival in frontotemporal dementia. Neurology. 2003;61:349–354. doi: 10.1212/01.WNL.0000078928.20107.52. PubMed DOI

Josephs K.A., Hodges J.R., Snowden J.S., Mackenzie I.R., Neumann M., Mann D.M., Dickson D.W. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol. 2011;122:137–153. doi: 10.1007/s00401-011-0839-6. PubMed DOI PMC

Rusina R., Ridzon P., Kulist’ák P., Keller O., Bartos A., Buncová M., Fialová L., Koukolík F., Matej R. Relationship between ALS and the degree of cognitive impairment, markers of neurodegeneration and predictors for poor outcome. A prospective study. Eur. J. Neurol. 2010;17:23–30. doi: 10.1111/j.1468-1331.2009.02717.x. PubMed DOI

Rohrer J.D., Guerreiro R., Vandrovcova J., Uphill J., Reiman D., Beck J., Isaacs A.M., Authier A., Ferrari R., Fox N.C., et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology. 2009;73:1451–1456. doi: 10.1212/WNL.0b013e3181bf997a. PubMed DOI PMC

Seelaar H., Schelhaas H.J., Azmani A., Küsters B., Rosso S., Majoor-Krakauer D., de Rijk M.C., Rizzu P., Brummelhuis M., van Doorn P.A., et al. TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations. Brain. 2007;130:1375–1385. doi: 10.1093/brain/awm024. PubMed DOI

Van Langenhove T., Van der Zee J., Van Broeckhoven C. The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum. Ann. Med. 2012;44:817–828. doi: 10.3109/07853890.2012.665471. PubMed DOI PMC

Cruts M., Gijselinck I., Van Langenhove T., Van der Zee J., Van Broeckhoven C. Current insights into the C9 or f72 repeat expansion diseases of the FTLD/ALS spectrum. Trends Neurosci. 2013;36:450–459. doi: 10.1016/j.tins.2013.04.010. PubMed DOI

Perrone F., Nguyen H.P., Van Mossevelde S., Moisse M., Sieben A., Santens P., De Bleecker J., Vandenbulcke M., Engelborghs S., Baets J., et al. Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients. Neurobiol. Aging. 2017;51:e9–e177. doi: 10.1016/j.neurobiolaging.2016.12.008. PubMed DOI

Lomen-Hoerth C., Murphy J., Langmore S., Kramer J.H., Olney R.K., Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology. 2003;8:1094–1097. doi: 10.1212/01.WNL.0000055861.95202.8D. PubMed DOI

Ringholz G.M., Appel S.H., Bradshaw M., Cooke N.A., Mosnik D.M., Schulz P.E. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005;65:586–590. doi: 10.1212/01.wnl.0000172911.39167.b6. PubMed DOI

Lillo P., Hodges J.R. Frontotemporal dementia and motor neurone disease: Overlapping clinic-pathological disorders. J. Clin. Neurosci. 2009;9:1131–1135. doi: 10.1016/j.jocn.2009.03.005. PubMed DOI

Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., et al. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology. 1998;51:1546–1554. doi: 10.1212/WNL.51.6.1546. PubMed DOI

Pasquier F., Petit H. Frontotemporal dementia: Its rediscovery. Eur. Neurol. 1997;8:1–6. doi: 10.1159/000112894. PubMed DOI

Zarei S., Carr K., Reiley L., Diaz K., Guerra O., Altamirano P.F., Pagani W., Lodin D., Orozco G., Chinea A., et al. A comprehensive review of amyotrophic lateral sclerosis. Surg. Neurol. Int. 2015;6:171. doi: 10.4103/2152-7806.169561. PubMed DOI PMC

De Jesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245–256. doi: 10.1016/j.neuron.2011.09.011. PubMed DOI PMC

Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310. PubMed DOI PMC

Tan R.H., Yang Y., Kim W.S., Dobson-Stone C., Kwok J.B., Kiernan M.C., Halliday G.M. Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis. Acta Neuropathol. Commun. 2017;5:76. doi: 10.1186/s40478-017-0480-2. PubMed DOI PMC

Mackenzie I.R., Neumann M., Baborie A., Sampathu D.M., Du Plessis D., Jaros E., Perry R.H., Trojanowski J.Q., Mann D.M., Lee V.M. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122:111–113. doi: 10.1007/s00401-011-0845-8. PubMed DOI PMC

Boeve B.F., Boylan K.B., Graff-Radford N.R., De Jesus-Hernandez M., Knopman D.S., Pedraza O., Vemuri P., Jones D., Lowe V., Murray M.E., et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain. 2012;3:765–783. doi: 10.1093/brain/aws004. PubMed DOI PMC

Mackenzie I.R., Nicholson A.M., Sarkar M., Messing J., Purice M.D., Pottier C., Annu K., Baker M., Perkerson R.B., Kurti A., et al. TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics. Neuron. 2017;95:808–816. doi: 10.1016/j.neuron.2017.07.025. PubMed DOI PMC

Oakes J.A., Davies M.C., Collins M.O. TBK1: A new player in ALS linking autophagy and neuroinflammation. Mol. Brain. 2017;10:5. doi: 10.1186/s13041-017-0287-x. PubMed DOI PMC

McKhann G.M., Albert M.S., Grossman M., Miller B., Dickson D., Trojanowski J.Q., Work Group on Frontotemporal Dementia and Pick’s Disease Clinical and pathological diagnosis of frontotemporal dementia: Report of the Work Group on Frontotemporal Dementia and Pick’s Disease. Clinical and pathological diagnosis of frontotemporal dementia: Report of the Work Group on Frontotemporal Dementia and Pick‘s Disease. Arch. Neurol. 2001;58:1803–1809. PubMed

Leigh P.N., Anderton B.H., Dodson A., Gallo J.M., Swash M., Power D.M. Ubiquitin deposits in anterior horn cells in motor neurone disease. Neurosci. Lett. 1988;93:197–203. doi: 10.1016/0304-3940(88)90081-X. PubMed DOI

Kwiatkowski T.J., Jr., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205–1208. doi: 10.1126/science.1166066. PubMed DOI

Vance C., Rogelj B., Hortobágyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208–1211. doi: 10.1126/science.1165942. PubMed DOI PMC

Amador-Ortiz C., Lin W.L., Ahmed Z., Personett D., Davies P., Duara R., Graff-Radford N.R., Hutton M.L., Dickson D.W. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer‘s disease. Ann. Neurol. 2007;61:435–445. doi: 10.1002/ana.21154. PubMed DOI PMC

Uryu K., Nakashima-Yasuda H., Forman M.S., Kwong L.K., Clark C.M., Grossman M., Miller B.L., Kretzschmar H.A., Lee V.M., Trojanowski J.Q., et al. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J. Neuropathol. Exp. Neurol. 2008;67:555–664. doi: 10.1097/NEN.0b013e31817713b5. PubMed DOI PMC

Higashi S., Iseki E., Yamamoto R., Minegishi M., Hino H., Fujisawa K., Togo T., Katsuse O., Uchikado H., Furukawa Y., et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer‘s disease and dementia with Lewy bodies. Brain Res. 2007;1184:284–294. doi: 10.1016/j.brainres.2007.09.048. PubMed DOI

Yokota O., Davidson Y., Arai T., Hasegawa M., Akiyama H., Ishizu H., Terada S., Sikkink S., Pickering-Brown S., Mann D.M., et al. Effect of topographical distribution of α-synuclein pathology on TDP-43 accumulation in Lewy body disease. Acta Neuropathol. 2010;120:789–801. doi: 10.1007/s00401-010-0731-9. PubMed DOI

Geser F., Martinez-Lage M., Kwong L.K., Lee V.M., Trojanowski J.Q. Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: The TDP-43 diseases. J. Neurol. 2009;256:1205–1214. doi: 10.1007/s00415-009-5069-7. PubMed DOI PMC

Josephs K.A., Whitwell J.L., Knopman D.S., Hu W.T., Stroh D.A., Baker M., Rademakers R., Boeve B.F., Parisi J.E., Smith G.E., et al. Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology. 2008;70:1850–1857. doi: 10.1212/01.wnl.0000304041.09418.b1. PubMed DOI PMC

Maharjan N., Künzli C., Buthey K., Saxena S. C9ORF72 Regulates Stress Granule Formation and Its Deficiency Impairs Stress Granule Assembly, Hypersensitizing Cells to Stress. Mol. Neurobiol. 2017;54:3062–3077. doi: 10.1007/s12035-016-9850-1. PubMed DOI

O’Rourke J.G., Bogdanik L., Yáñez A., Lall D., Wolf A.J., Muhammad A.K., Ho R., Carmona S., Vit J.P., Zarrow J., et al. C9orf72 is required for proper macrophage and microglial function in mice. Science. 2016;351:324–329. doi: 10.1126/science.aaf1064. PubMed DOI PMC

Sullivan P.M., Zhou X., Robins A.M., Paushter D.H., Kim D., Smolka M.B., Hu F. The ALS/FTLD associated protein C9orf72 associates with SMCR8 and WDR41 to regulate the autophagy-lysosome pathway. Acta Neuropathol. Commun. 2016;4:51. doi: 10.1186/s40478-016-0324-5. PubMed DOI PMC

Dafinca R., Scaber J., Ababneh N., Lalic T., Weir G., Christian H., Vowles J., Douglas A.G., Fletcher-Jones A., Browne C., et al. C9orf72 Hexanucleotide Expansions Are Associated with Altered Endoplasmic Reticulum Calcium Homeostasis and Stress Granule Formation in Induced Pluripotent Stem Cell-Derived Neurons from Patients with Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Stem Cells. 2016;34:2063–2078. PubMed PMC

Pankiv S., Clausen T.H., Lamark T., Brech A., Bruun J.A., Outzen H., Overvatn A., Bjorkoy G., Johansen T. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J. Biol. Chem. 2007;282:24131–24145. doi: 10.1074/jbc.M702824200. PubMed DOI

Matěj R., Rohan Z., Holada K., Olejár T. The contribution of proteinase-activated receptors to intracellular signaling, transcellular transport and autophagy in Alzheimer‘s disease. Curr. Alzheimer Res. 2015;12:2–12. doi: 10.2174/1567205012666141218123202. PubMed DOI

Liu W.J., Ye L., Huang W.F., Guo L.J., Xu Z.G., Wu H.L., Yang C., Liu H.F. p62 links the autophagy pathway and the ubiqutin-proteasome system upon ubiquitinated protein degradation. Cell Mol. Biol. Lett. 2016;21:29. doi: 10.1186/s11658-016-0031-z. PubMed DOI PMC

Seibenhener M.L., Du Y., Diaz-Meco M.T., Moscat J., Wooten M.C., Wooten M.W. A role for sequestosome 1/p62 in mitochondrial dynamics, import and genome integrity. Biochim. Biophys. Acta. 2013;1833:452–459. doi: 10.1016/j.bbamcr.2012.11.004. PubMed DOI PMC

Rubino E., Rainero I., Chiò A., Rogaeva E., Galimberti D., Fenoglio P., Grinberg Y., Isaia G., Calvo A., Gentile S., et al. SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology. 2012;79:1556–1562. doi: 10.1212/WNL.0b013e31826e25df. PubMed DOI PMC

Lindberg M.J., Byström R., Boknäs N., Andersen P.M., Oliveberg M. Systematically perturbed folding patterns of amyotrophic lateral sclerosis (ALS)-associated SOD1 mutants. Proc. Natl. Acad. Sci. USA. 2005;102:9754–9759. doi: 10.1073/pnas.0501957102. PubMed DOI PMC

Peters O.M., Ghasemi M., Brown R.H., Jr. Emerging mechanisms of molecular pathology in ALS. J. Clin. Invest. 2015;25:1767–1779. doi: 10.1172/JCI71601. PubMed DOI PMC

Kiriyama Y., Nochi H. The Function of Autophagy in Neurodegenerative Diseases. Int. J. Mol. Sci. 2015;16:26797–26812. doi: 10.3390/ijms161125990. PubMed DOI PMC

Forsberg K., Graffmo K., Pakkenberg B., Weber M., Nielsen M., Marklund S., Brännström T., Andersen P.M. Misfolded SOD1 inclusions in patients with mutations in C9orf72 and other ALS/FTD-associated genes. J. Neurol. Neurosurg. Psychiatry. 2019;90:861–869. doi: 10.1136/jnnp-2018-319386. PubMed DOI PMC

Matej R., Botond G., László L., Kopitar-Jerala N., Rusina R., Budka H., Kovacs G.G. Increased neuronal Rab5 immunoreactive endosomes do not colocalize with TDP-43 in motor neuron disease. Exp. Neurol. 2010;225:133–139. doi: 10.1016/j.expneurol.2010.06.004. PubMed DOI

Aguzzi A., O’Connor T. Protein aggregation diseases: Pathogenicity and therapeutic perspectives. Nat. Rev. Drug Discov. 2010;9:237–248. doi: 10.1038/nrd3050. PubMed DOI

Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787–795. doi: 10.1038/nature05292. PubMed DOI

Sasaki S., Horie Y., Iwata M. Mitochondrial alterations in dorsal root ganglion cells in sporadic amyotrophic lateral sclerosis. Acta Neuropathol. 2007;114:633–639. doi: 10.1007/s00401-007-0299-1. PubMed DOI

Beal M.F., Ferrante R.J., Browne S.E., Matthews R.T., Kowall N.W., Brown R.H., Jr. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann. Neurol. 1997;42:644–654. doi: 10.1002/ana.410420416. PubMed DOI

Kann O., Kovács R. Mitochondria and neuronal activity. Am. J. Physiol. Cell Physiol. 2007;292:C641–C657. doi: 10.1152/ajpcell.00222.2006. PubMed DOI

Nicholls D.G., Budd S.L. Mitochondria and neuronal survival. Physiol. Rev. 2000;80:315–360. doi: 10.1152/physrev.2000.80.1.315. PubMed DOI

Engl E., Attwell D. Non-signalling energy use in the brain. J. Physiol. 2015;593:3417–3429. doi: 10.1113/jphysiol.2014.282517. PubMed DOI PMC

Rizzuto R., De Stefani D., Raffaello A., Mammucari C. Mitochondria as sensors and regulators of calcium signalling. Nat. Rev. Mol. Cell Biol. 2012;13:566–578. doi: 10.1038/nrm3412. PubMed DOI

Deng J., Yang M., Chen Y., Chen X., Liu J., Sun S., Cheng H., Li Y., Bigio E.H., Mesulam M., et al. FUS Interacts with HSP60 to Promote Mitochondrial Damage. PLoS Genet. 2015;11:1005357. doi: 10.1371/journal.pgen.1005357. PubMed DOI PMC

Wang W., Wang L., Lu J., Siedlak S.L., Fujioka H., Liang J., Jiang S., Ma X., Jiang Z., da Rocha E.L., et al. The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nat. Med. 2016;22:869–878. doi: 10.1038/nm.4130. PubMed DOI PMC

Lopez-Gonzalez R., Lu Y., Gendron T.F., Karydas A., Tran H., Yang D., Petrucelli L., Miller B.L., Almeida S., Gao F.B. Poly (GR) in C9ORF72-Related ALS/FTD Compromises Mitochondrial Function and Increases Oxidative Stress and DNA Damage in iPSC-Derived Motor Neurons. Neuron. 2016;92:383–391. doi: 10.1016/j.neuron.2016.09.015. PubMed DOI PMC

Bannwarth S., Ait-El-Mkadem S., Chaussenot A., Genin E.C., Lacas-Gervais S., Fragaki K., Berg-Alonso L., Kageyama Y., Serre V., Moore D.G., et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain. 2014;137:2329–2345. doi: 10.1093/brain/awu138. PubMed DOI PMC

Genin E.C., Plutino M., Bannwarth S., Villa E., Cisneros-Barroso E., Roy M., Ortega-Vila B., Fragaki K., Lespinasse F., Pinero-Martos E., et al. CHCHD10 mutations promote loss of mitochondrial cristae junctions with impaired mitochondrial genome maintenance and inhibition of apoptosis. EMBO Mol. Med. 2016;8:58–72. doi: 10.15252/emmm.201505496. PubMed DOI PMC

Schapira A.H. Mitochondrial diseases. Lancet. 2012;379:1825–1834. doi: 10.1016/S0140-6736(11)61305-6. PubMed DOI

Hill S.J., Mordes D.A., Cameron L.A., Neuberg D.S., Landini S., Eggan K., Livingston D.M. Two familial ALS proteins function in prevention/repair of transcription-associated DNA damage. Proc. Natl. Acad. Sci. USA. 2016;113:E7701–E7709. doi: 10.1073/pnas.1611673113. PubMed DOI PMC

Mastrocola A.S., Kim S.H., Trinh A.T., Rodenkirch L.A., Tibbetts R.S. The RNA-binding protein fused in sarcoma (FUS) functions downstream of poly(ADP-ribose) polymerase (PARP) in response to DNA damage. J. Biol. Chem. 2013;288:24731–24741. doi: 10.1074/jbc.M113.497974. PubMed DOI PMC

Wang W.Y., Pan L., Su S.C., Quinn E.J., Sasaki M., Jimenez J.C., Mackenzie I.R., Huang E.J., Tsai L.H. Interaction of FUS and HDAC1 regulates DNA damage response and repair in neurons. Nat. Neurosci. 2013;16:1383–1391. doi: 10.1038/nn.3514. PubMed DOI PMC

Paronetto M.P., Miñana B., Valcárcel J. The Ewing sarcoma protein regulates DNA damage-induced alternative splicing. Mol. Cell. 2011;43:353–568. doi: 10.1016/j.molcel.2011.05.035. PubMed DOI

Skourti-Stathaki K., Proudfoot N.J., Gromak N. Human senataxin resolves RNA/DNA hybrids formed at transcriptional pause sites to promote Xrn2-dependent termination. Mol. Cell. 2011;42:794–805. doi: 10.1016/j.molcel.2011.04.026. PubMed DOI PMC

Izhar L., Adamson B., Ciccia A., Lewis J., Pontano-Vaites L., Leng Y., Liang A.C., Westbrook T.F., Harper J.W., Elledge S.J. A Systematic Analysis of Factors Localized to Damaged Chromatin Reveals PARP-Dependent Recruitment of Transcription Factors. Cell Rep. 2011;11:1486–1500. doi: 10.1016/j.celrep.2015.04.053. PubMed DOI PMC

Liu X.A., Rizzo V., Puthanveettil S.V. Pathologies of axonal transport in neurodegenerative diseases. Transl. Neurosci. 2012;3:355–372. doi: 10.2478/s13380-012-0044-7. PubMed DOI PMC

Millecamps S., Julien J.P. Axonal transport deficits and neurodegenerative diseases. Nat. Rev. Neurosci. 2013;14:161–176. doi: 10.1038/nrn3380. PubMed DOI

De Vos K.J., Hafezparast M. Neurobiology of axonal transport defects in motor neuron diseases: Opportunities for translational research? Neurobiol. Dis. 2017;105:283–299. doi: 10.1016/j.nbd.2017.02.004. PubMed DOI PMC

Sleigh J.N., Rossor A.M., Fellows A.D., Tosolini A.P., Schiavo G. Axonal transport and neurological disease. Nat. Rev. Neurol. 2019;15:691–703. doi: 10.1038/s41582-019-0257-2. PubMed DOI

Anderson E.N., White J.A., Gunawardena S. Axonal transport and neurodegenerative disease: Vesicle-motor complex formation and their regulation. Degener. Neurol. Neuromuscul. Dis. 2014;4:29–47. PubMed PMC

La Monte B.H., Wallace K.E., Holloway B.A., Shelly S.S., Ascaño J., Tokito M., Van Winkle T., Howland D.S., Holzbaur E.L. Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron. 2002;347:15–27. PubMed

Puls I., Oh S.J., Sumner C.J., Wallace K.E., Floeter M.K., Mann E.A., Kennedy W.R., Wendelschafer-Crabb G., Vortmeyer A., Powers R., et al. Distal spinal and bulbar muscular atrophy caused by dynactin mutation. Ann. Neurol. 2005;57:687–694. doi: 10.1002/ana.20468. PubMed DOI PMC

Münch C., Sedlmeier R., Meyer T., Homberg V., Sperfeld A.D., Kurt A., Prudlo J., Peraus G., Hanemann C.O., Stumm G., et al. Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology. 2004;637:724–726. doi: 10.1212/01.WNL.0000134608.83927.B1. PubMed DOI

Lawrence C.J., Dawe R.K., Christie K.R., Cleveland D.W., Dawson S.C., Endow S.A., Goldstein L.S., Goodson H.V., Hirokawa N., Howard J., et al. A standardized kinesin nomenclature. J. Cell Biol. 2004;167:19–22. doi: 10.1083/jcb.200408113. PubMed DOI PMC

Clark J.A., Yeaman E.J., Blizzard C.A., Chuckowree J.A., Dickson T.C. A Case for Microtubule Vulnerability in Amyotrophic Lateral Sclerosis: Altered Dynamics During Disease. Front. Cell Neurosci. 2016;13:204. doi: 10.3389/fncel.2016.00204. PubMed DOI PMC

Smith B.N., Ticozzi N., Fallini C., Gkazi A.S., Topp S., Kenna K.P., Scotter E.L., Kost J., Keagle P., Miller J.W., et al. Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. Neuron. 2014;84:324–331. doi: 10.1016/j.neuron.2014.09.027. PubMed DOI PMC

Cai D., McEwen D.P., Martens J.R., Meyhofer E., Verhey K.J. Single molecule imaging reveals differences in microtubule track selection between Kinesin motors. PLoS Biol. 2009;7:1000216. doi: 10.1371/journal.pbio.1000216. PubMed DOI PMC

Khalil B., Morderer D., Price P.L., Liu F., Rossoll W. mRNP assembly, axonal transport, and local translation in neurodegenerative diseases. Brain Res. 2018;1693:75–91. doi: 10.1016/j.brainres.2018.02.018. PubMed DOI PMC

Harrison A.F., Shorter J. RNA-binding proteins with prion-like domains in health and disease. Biochem. J. 2017;474:1417–1438. doi: 10.1042/BCJ20160499. PubMed DOI PMC

Taylor J.P., Brown R.H., Jr., Cleveland D.W. Decoding ALS: From genes to mechanism. Nature. 2016;539:197–206. doi: 10.1038/nature20413. PubMed DOI PMC

Brangwynne C.P., Mitchison T.J., Hyman A.A. Active liquid-like behavior of nucleoli determines their size and shape in Xenopus laevis oocytes. Proc. Natl. Acad. Sci. USA. 2011;108:4334–4339. doi: 10.1073/pnas.1017150108. PubMed DOI PMC

Huang S., Spector D.L. U1 and U2 small nuclear RNAs are present in nuclear speckles. Proc. Natl. Acad. Sci. USA. 1992;89:305–308. doi: 10.1073/pnas.89.1.305. PubMed DOI PMC

Sheth U., Parker R. Decapping and decay of messenger RNA occur in cytoplasmic processing bodies. Science. 2003;300:805–808. doi: 10.1126/science.1082320. PubMed DOI PMC

Xue Y.C., Ng C.S., Xiang P., Liu H., Zhang K., Mohamud Y., Luo H. Dysregulation of RNA-Binding Proteins in Amyotrophic Lateral Sclerosis. Front. Mol. Neurosci. 2020;29:78. doi: 10.3389/fnmol.2020.00078. PubMed DOI PMC

Colombrita C., Zennaro E., Fallini C., Weber M., Sommacal A., Buratti E., Silani V., Ratti A. TDP-43 is recruited to stress granules in conditions of oxidative insult. J. Neurochem. 2009;111:1051–1061. doi: 10.1111/j.1471-4159.2009.06383.x. PubMed DOI

Liu-Yesucevitz L., Bilgutay A., Zhang Y.J., Vanderweyde T., Citro A., Mehta T., Zaarur N., McKee A., Bowser R., Sherman M., et al. Tar DNA binding protein-43 (TDP-43) associates with stress granules: Analysis of cultured cells and pathological brain tissue. PLoS ONE. 2010;5:13250. doi: 10.1371/journal.pone.0013250. PubMed DOI PMC

Parker S.J., Meyerowitz J., James J.L., Liddell J.R., Crouch P.J., Kanninen K.M., White A.R. Endogenous TDP-43 localized to stress granules can subsequently form protein aggregates. Neurochem. Int. 2012;60:415–424. doi: 10.1016/j.neuint.2012.01.019. PubMed DOI

Protter D.S.W., Parker R. Principles and Properties of Stress Granules. Trends Cell Biol. 2016;26:668–679. doi: 10.1016/j.tcb.2016.05.004. PubMed DOI PMC

Johnson B.S., Snead D., Lee J.J., McCaffery J.M., Shorter J., Gitler A.D. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J. Biol. Chem. 2009;284:20329–20339. doi: 10.1074/jbc.M109.010264. PubMed DOI PMC

Lagier-Tourenne C., Polymenidou M., Cleveland D.W. TDP-43 and FUS/TLS: Emerging roles in RNA processing and neurodegeneration. Hum. Mol. Genet. 2010;5:46–64. doi: 10.1093/hmg/ddq137. PubMed DOI PMC

Lagier-Tourenne C., Cleveland D.W. Rethinking ALS: The FUS about TDP-43. Cell. 2009;136:1001–1004. doi: 10.1016/j.cell.2009.03.006. PubMed DOI PMC

Dormann D., Haass C. TDP-43 and FUS: A nuclear affair. Trends Neurosci. 2011;34:339–348. doi: 10.1016/j.tins.2011.05.002. PubMed DOI

Baradaran-Heravi Y., Van Broeckhoven C., Van der Zee J. Stress granule mediated protein aggregation and underlying gene defects in the FTD-ALS spectrum. Neurobiol. Dis. 2020;134:104639. doi: 10.1016/j.nbd.2019.104639. PubMed DOI

Collins M., Riascos D., Kovalik T., An J., Krupa K., Hood B.L., Conrads T.P., Renton A.E., Traynor B.J., Bowser R. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients. Acta Neuropathol. 2012;124:717–732. doi: 10.1007/s00401-012-1045-x. PubMed DOI PMC

Anderson P., Kedersha N. Visibly stressed: The role of eIF2, TIA-1, and stress granules in protein translation. Cell Stress Chaperones. 2002;7:213–221. doi: 10.1379/1466-1268(2002)007<0213:VSTROE>2.0.CO;2. PubMed DOI PMC

Kedersha N.L., Gupta M., Li W., Miller I., Anderson P. RNA-binding proteins TIA-1 and TIAR link the phosphorylation of eIF-2 alpha to the assembly of mammalian stress granules. J. Cell Biol. 1999;1471:431–442. PubMed PMC

Komine O., Yamanaka K. Neuroinflammation in motor neuron disease. Nagoya J. Med. Sci. 2015;77:537–549. PubMed PMC

Liddelow S.A., Guttenplan K.A., Clarke L.E., Bennett F.C., Bohlen C.J., Schirmer L., Bennett M.L., Münch A.E., Chung W.S., Peterson T.C., et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481–487. doi: 10.1038/nature21029. PubMed DOI PMC

Irwin D., Lippa C.F., Rosso A. Progranulin (PGRN) expression in ALS: An immunohistochemical study. J. Neurol. Sci. 2009;276:9–13. doi: 10.1016/j.jns.2008.08.024. PubMed DOI

Freischmidt A., Wieland T., Richter B., Ruf W., Schaeffer V., Müller K., Marroquin N., Nordin F., Hübers A., Weydt P., et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 2015;18:631–636. doi: 10.1038/nn.4000. PubMed DOI

Lall D., Baloh R.H. Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia. J. Clin. Invest. 2017;127:3250–3258. doi: 10.1172/JCI90607. PubMed DOI PMC

Nicholson J.K., Holmes E., Kinross J., Burcelin R., Gibson G., Jia W., Pettersson S. Host-gut microbiota metabolic interactions. Science. 2012;336:1262–1267. doi: 10.1126/science.1223813. PubMed DOI

Rothhammer V., Borucki D.M., Tjon E.C., Takenaka M.C., Chao C.C., Ardura-Fabregat A., de Lima K.A., Gutiérrez-Vázquez C., Hewson P., Staszewski O., et al. Microglial control of astrocytes in response to microbial metabolites. Nature. 2018;557:724–728. doi: 10.1038/s41586-018-0119-x. PubMed DOI PMC

Jangi S., Gandhi R., Cox L.M., Li N., Von Glehn F., Yan R., Patel B., Mazzola M.A., Liu S., Glanz B.L., et al. Alterations of the human gut microbiome in multiple sclerosis. Nat. Commun. 2016;7:12015. doi: 10.1038/ncomms12015. PubMed DOI PMC

Sharon G., Cruz N.J., Kang D.W., Gandal M.J., Wang B., Kim Y.M., Zink E.M., Casey C.P., Taylor B.C., Lane C.J., et al. Human Gut Microbiota from Autism Spectrum Disorder Promote Behavioral Symptoms in Mice. Cell. 2019;177:1600–1618. doi: 10.1016/j.cell.2019.05.004. PubMed DOI PMC

Blacher E., Levy M., Tatirovsky E., Elinav E. Microbiome-Modulated Metabolites at the Interface of Host Immunity. J. Immunol. 2017;198:572–580. doi: 10.4049/jimmunol.1601247. PubMed DOI

Wang Y., Kasper L.H. The role of microbiome in central nervous system disorders. Brain Behav. Immun. 2014;38:1–12. doi: 10.1016/j.bbi.2013.12.015. PubMed DOI PMC

Longstreth W.T., Jr., Meschke J.S., Davidson S.K., Smoot L.M., Smoot J.C., Koepsell T.D. Hypothesis: A motor neuron toxin produced by a clostridial species residing in gut causes ALS. Med. Hypotheses. 2005;64:1153–1156. doi: 10.1016/j.mehy.2004.07.041. PubMed DOI

Brenner D., Hiergeist A., Adis C., Mayer B., Gessner A., Ludolph A.C., Weishaupt J.H. The fecal microbiome of ALS patients. Neurobiol. Aging. 2018;61:132–137. doi: 10.1016/j.neurobiolaging.2017.09.023. PubMed DOI

Rowin J., Xia Y., Jung B., Sun J. Gut inflammation and dysbiosis in human motor neuron disease. Physiol. Rep. 2017;5:13443. doi: 10.14814/phy2.13443. PubMed DOI PMC

Renton A.E., Chiò A., Traynor B.J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014;17:17–23. doi: 10.1038/nn.3584. PubMed DOI PMC

Sieben A., Van Langenhove T., Engelborghs S., Martin J.J., Boon P., Cras P., De Deyn P.P., Santens P., Van Broeckhoven C., Cruts M. The genetics and neuropathology of frontotemporal lobar degeneration. Acta Neuropathol. 2012;124:353–372. doi: 10.1007/s00401-012-1029-x. PubMed DOI PMC

Luigetti M., Lattante S., Zollino M., Conte A., Marangi G., Del Grande A., Sabatelli M. SOD1 G93D sporadic amyotrophic lateral sclerosis (SALS) patient with rapid progression and concomitant novel ANG variant. Neurobiol. Aging. 2011;32:e15–e18. doi: 10.1016/j.neurobiolaging.2011.04.004. PubMed DOI

Chiò A., Restagno G., Brunetti M., Ossola I., Calvo A., Canosa A., Moglia C., Floris G., Tacconi P., Marrosu F., et al. ALS/FTD phenotype in two Sardinian families carrying both C9ORF72 and TARDBP mutations. J. Neurol. Neurosurg. Psychiatry. 2012;83:730–733. doi: 10.1136/jnnp-2012-302219. PubMed DOI PMC

Van Blitterswijk M., Van Es M.A., Hennekam E.A., Dooijes D., Van Rheenen W., Medic J., Bourque P.R., Schelhaas H.J., van der Kooi A.J., de Visser M., et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum. Mol. Genet. 2012;21:3776–3784. doi: 10.1093/hmg/dds199. PubMed DOI

Ghasemi M., Brown R.H., Jr. Genetics of Amyotrophic Lateral Sclerosis. Cold Spring Harb. Perspect. Med. 2018;8:024125. doi: 10.1101/cshperspect.a024125. PubMed DOI PMC

Mahoney C.J., Beck J., Rohrer J.D., Lashley T., Mok K., Shakespeare T.Y., Yeatman T., Warrington E.K., Schott J.M., Fox N.C., et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: Clinical, neuroanatomical and neuropathological features. Brain. 2012;135:736–750. doi: 10.1093/brain/awr361. PubMed DOI PMC

De Majo M., Topp S.D., Smith B.N., Nishimura A.L., Chen H.J., Gkazi A.S., Miller J., Wong C.H., Vance C., Baas F., et al. ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function. Neurobiol. Aging. 2018;71:266. doi: 10.1016/j.neurobiolaging.2018.06.015. PubMed DOI PMC

Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O’Regan J.P., Deng H.X. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59–62. doi: 10.1038/362059a0. PubMed DOI

Sreedharan J., Blair I.P., Tripathi V.B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J.C., Williams K.L., Buratti E., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668–1672. doi: 10.1126/science.1154584. PubMed DOI PMC

Borroni B., Bonvicini C., Alberici A., Buratti E., Agosti C., Archetti S., Papetti A., Stuani C., Di Luca M., Gennarelli M., et al. Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease. Hum. Mutat. 2009;30:E974–E983. doi: 10.1002/humu.21100. PubMed DOI

Gelpi E., Van der Zee J., Turon Estrada A., Van Broeckhoven C., Sanchez-Valle R. TARDBP mutation p.Ile383Val associated with semantic dementia and complex proteinopathy. Neuropathol. Appl. Neurobiol. 2014;402:225–230. doi: 10.1111/nan.12063. PubMed DOI

Kabashi E., Valdmanis P.N., Dion P., Spiegelman D., Mc Conkey B.J., Vande Velde C., Bouchard J.P., Lacomblez L., Pochigaeva K., Salachas F., et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008;40:572–574. doi: 10.1038/ng.132. PubMed DOI

Greenway M.J., Andersen P.M., Russ C., Ennis S., Cashman S., Donaghy C., Patterson V., Swingler R., Kieran D., Prehn J., et al. ANG mutations segregate with familial and ’sporadic’ amyotrophic lateral sclerosis. Nat. Genet. 2006;38:411–413. doi: 10.1038/ng1742. PubMed DOI

Maruyama H., Morino H., Ito H., Izumi Y., Kato H., Watanabe Y., Kinoshita Y., Kamada M., Nodera H., Suzuki H., et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223–226. doi: 10.1038/nature08971. PubMed DOI

Gijselinck I., Van Langenhove T., Van der Zee J., Sleegers K., Philtjens S., Kleinberger G., Janssens J., Bettens K., Van Cauwenberghe C., Pereson S., et al. A C9 or f72 promoter repeat expansion in a Flanders-Belgian cohortwith disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: A gene identification study. Lancet Neurol. 2012;11:54–65. doi: 10.1016/S1474-4422(11)70261-7. PubMed DOI

Chiò A., Traynor B.J., Lombardo F., Fimognari M., Calvo A., Ghiglione P., Mutani R., Restagno G. Prevalence of SOD1 mutations in the Italian ALS population. Neurology. 2008;70:533–537. doi: 10.1212/01.wnl.0000299187.90432.3f. PubMed DOI

Battistini S., Giannini F., Greco G., Bibbò G., Ferrera L., Marini V., Causarano R., Casula M., Lando G., Patrosso M.C., et al. SOD1 mutations in amyotrophic lateral sclerosis. Results from a multicenter Italian study. J. Neurol. 2005;252:782–788. doi: 10.1007/s00415-005-0742-y. PubMed DOI

Cudkowicz M.E., Mc Kenna-Yasek D., Sapp P.E., Chin W., Geller B., Hayden D.L., Schoenfeld D.A., Hosler B.A., Horvitz H.R., Brown R.H. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann. Neurol. 1997;41:210–221. doi: 10.1002/ana.410410212. PubMed DOI

Abel O., Powell J.F., Andersen P.M., Al-Chalabi A. ALSoD: A user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum. Mutat. 2012;33:1345–1351. doi: 10.1002/humu.22157. PubMed DOI

Ilieva H., Polymenidou M., Cleveland D.W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 2009;187:761–772. doi: 10.1083/jcb.200908164. PubMed DOI PMC

Hirano A., Donnenfeld H., Sasaki S., Nakano I. Fine structural observations of neurofilamentous changes in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 1984;43:461–470. doi: 10.1097/00005072-198409000-00001. PubMed DOI

Bergemalm D., Jonsson P.A., Graffmo K.S., Andersen P.M., Brännström T., Rehnmark A., Marklund S.L. Overloading of stable and exclusion of unstable human superoxide dismutase-1 variants in mitochondria of murine amyotrophic lateral sclerosis models. J. Neurosci. 2006;26:4147–4154. doi: 10.1523/JNEUROSCI.5461-05.2006. PubMed DOI PMC

Deng H.X., Shi Y., Furukawa Y., Zhai H., Fu R., Liu E., Gorrie G.H., Khan M.S., Hung W.-Y., Huang W.-Y., et al. Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc. Natl. Acad. Sci. USA. 2006;103:7142–7147. doi: 10.1073/pnas.0602046103. PubMed DOI PMC

Liu J., Lillo C., Jonsson P.A., Vande Velde C., Ward C.M., Miller T.M., Subramaniam J.R., Rothstein J.D., Marklund S., Andersen P.M., et al. Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron. 2004;43:5–17. doi: 10.1016/j.neuron.2004.06.016. PubMed DOI

Pickles S., Semmler S., Broom H.R., Destroismaisons L., Legroux L., Arbour N., Meiering E., Cashman N.R., Vande Velde C. ALS-linked misfolded SOD1 species have divergent impacts on mitochondria. Acta Neuropathol. Commun. 2016;4:43. doi: 10.1186/s40478-016-0313-8. PubMed DOI PMC

Israelson A., Arbel N., Da Cruz S., Ilieva H., Yamanaka K., Shoshan-Barmatz V., Cleveland D.W. Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron. 2010;67:575–587. doi: 10.1016/j.neuron.2010.07.019. PubMed DOI PMC

Wang W., Li L., Lin W.L., Dickson D.W., Petrucelli L., Zhang T., Wang X. The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons. Hum. Mol. Genet. 2013;22:4706–4719. doi: 10.1093/hmg/ddt319. PubMed DOI PMC

Bali T., Self W., Liu J., Siddique T., Wang L.H., Bird T.D., Ratti E., Atassi N., Boylan K.B., Glass J.D., et al. Defining SOD1 ALS natural history to guide therapeutic clinical trial design. J. Neurol. Neurosurg. Psychiatry. 2017;88:99–105. doi: 10.1136/jnnp-2016-313521. PubMed DOI PMC

Aksoy H., Dean G., Elian M., Deng H.X., Deng G., Juneja T., Storey E., McKinlay Gardner R.J., Jacob R.L., Laing N.G., et al. A4T mutation in the SOD1 gene causing familial amyotrophic lateral sclerosis. Neuroepidemiology. 2003;22:235–238. doi: 10.1159/000070564. PubMed DOI

Régal L., Vanopdenbosch L., Tilkin P., Van den Bosch L., Thijs V., Sciot R., Robberecht W. The G93C mutation in superoxide dismutase 1: Clinicopathologic phenotype and prognosis. Arch. Neurol. 2006;63:262–267. doi: 10.1001/archneur.63.2.262. PubMed DOI

Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130–133. doi: 10.1126/science.1134108. PubMed DOI

Pesiridis G.S., Lee V.M., Trojanowski J.Q. Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum. Mol. Genet. 2009;18:156–162. doi: 10.1093/hmg/ddp303. PubMed DOI PMC

Rohn T.T. Cytoplasmic inclusions of TDP-43 in neurodegenerative diseases: A potential role for caspases. Histol. Histopathol. 2009;24:1081–1086. PubMed PMC

Freibaum B.D., Chitta R.K., High A.A., Taylor J.P. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J. Proteome Res. 2010;9:1104–1120. doi: 10.1021/pr901076y. PubMed DOI PMC

Liscic R.M., Grinberg L.T., Zidar J., Gitcho M.A., Cairns N.J. ALS and FTLD: Two faces of TDP-43 proteinopathy. Eur. J. Neurol. 2008;15:772–780. doi: 10.1111/j.1468-1331.2008.02195.x. PubMed DOI PMC

Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., Mann D., Tsuchiya K., Yoshida M., Hashizume Y., et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602–611. doi: 10.1016/j.bbrc.2006.10.093. PubMed DOI

Parkinson N., Ince P.G., Smith M.O., Highley R., Skibinski G., Andersen P.M., Morrison K.E., Pall H.S., Hardiman O., Collinge J., et al. ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B) Neurology. 2006;67:1074–1077. doi: 10.1212/01.wnl.0000231510.89311.8b. PubMed DOI

Benajiba L., Le Ber I., Camuzat A., Lacoste M., Thomas-Anterion C., Couratier P., Legallic S., Salachas F., Hannequin D., Decousus M., et al. TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann. Neurol. 2009;65:470–473. doi: 10.1002/ana.21612. PubMed DOI

Recabarren-Leiva D., Alarcón M. New insights into the gene expression associated to amyotrophic lateral sclerosis. Life Sci. 2018;193:110–123. doi: 10.1016/j.lfs.2017.12.016. PubMed DOI

Volk A.E., Weishaupt J.H., Andersen P.M., Ludolph A.C., Kubisch C. Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis. Med. Genet. 2018;30:252–258. doi: 10.1007/s11825-018-0185-3. PubMed DOI PMC

Maurel C., Dangoumau A., Marouillat S., Brulard C., Chami A., Hergesheimer R., Corcia P., Blasco H., Andres C.R., Vourc’h P., et al. Causative Genes in Amyotrophic Lateral Sclerosis and Protein Degradation Pathways: A Link to Neurodegeneration. Mol. Neurobiol. 2018;55:6480–6499. doi: 10.1007/s12035-017-0856-0. PubMed DOI

Kanai Y., Okada Y., Tanaka Y., Harada A., Terada S., Hirokawa N. KIF5C, a novel neuronal kinesin enriched in motor neurons. J. Neurosci. 2000;20:6374–6384. doi: 10.1523/JNEUROSCI.20-17-06374.2000. PubMed DOI PMC

Wang L., Brown A. A hereditary spastic paraplegia mutation in kinesin-1A/KIF5A disrupts neurofilament transport. Mol. Neurodegener. 2010;15:52. doi: 10.1186/1750-1326-5-52. PubMed DOI PMC

Xia C.H., Roberts E.A., Her L.S., Liu X., Williams D.S., Cleveland D.W., Goldstein L.S. Abnormal neurofilament transport caused by targeted disruption of neuronal kinesin heavy chain KIF5A. J. Cell Biol. 2003;161:55–66. doi: 10.1083/jcb.200301026. PubMed DOI PMC

Al-Chalabi A., Andersen P.M., Nilsson P., Chioza B., Andersson J.L., Russ C., Shaw C.E., Powell J.F., Leigh P.N. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum. Mol. Genet. 1999;8:157–164. doi: 10.1093/hmg/8.2.157. PubMed DOI

Chevalier-Larsen E., Holzbaur E.L. Axonal transport and neurodegenerative disease. Biochim. Biophys. Acta. 2006;762:1094–1108. doi: 10.1016/j.bbadis.2006.04.002. PubMed DOI

Guo W., Naujock M., Fumagalli L., Vandoorne T., Baatsen P., Boon R., Ordovás L., Patel A., Welters M., Vanwelden T., et al. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat. Commun. 2017;8:861. doi: 10.1038/s41467-017-00911-y. PubMed DOI PMC

Alomo G.M., Manfredi G. Exploring new pathways of neurodegeneration in ALS: The role of mitochondria quality control. Brain Res. 2015;1607:36–46. PubMed PMC

Smith E.F., Shaw P.J., De Vos K.J. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci. Lett. 2019;710:132933. doi: 10.1016/j.neulet.2017.06.052. PubMed DOI

Fitzgerald K.A., Mc Whirter S.M., Faia K.L., Rowe D.C., Latz E., Golenbock D.T., Coyle A.J., Liao S.M., Maniatis T. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 2003;4:491–496. doi: 10.1038/ni921. PubMed DOI

Thurston T.L., Ryzhakov G., Bloor S., Von Muhlinen N., Randow F. The TBK1 adaptor and autophagy receptor NDP52 restricts the proliferation of ubiquitin-coated bacteria. Nat. Immunol. 2009;10:1215–1221. doi: 10.1038/ni.1800. PubMed DOI

Pilli M., Arko-Mensah J., Ponpuak M., Roberts E., Master S., Mandell M.A., Dupont N., Ornatowski W., Jiang S., Bradfute S.B., et al. TBK-1 promotes autophagy-mediated antimicrobial defense by controlling autophagosome maturation. Immunity. 2012;37:223–234. doi: 10.1016/j.immuni.2012.04.015. PubMed DOI PMC

Clément J.F., Meloche S., Servant M.J. The IKK-related kinases: From innate immunity to oncogenesis. Cell Res. 2008;18:889–899. doi: 10.1038/cr.2008.273. PubMed DOI

Pottier C., Bieniek K.F., Finch N., Van de Vorst M., Baker M., Perkersen R., Brown P., Ravenscroft T., van Blitterswijk M., Nicholson A.M., et al. Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol. 2015;130:77–92. doi: 10.1007/s00401-015-1436-x. PubMed DOI PMC

Zhou Z.D., Saw W.T., Tan E.K. Mitochondrial CHCHD-Containing Proteins: Physiologic Functions and Link with Neurodegenerative Diseases. Mol. Neurobiol. 2017;54:5534–5546. doi: 10.1007/s12035-016-0099-5. PubMed DOI

Johnson J.O., Glynn S.M., Gibbs J.R., Nalls M.A., Sabatelli M., Restagno G., Drory V.E., Chiò A., Rogaeva E., Traynor B.J. Mutations in the CHCHD10 gene are a common cause of familial amyotrophic lateral sclerosis. Brain. 2014;137:e311. doi: 10.1093/brain/awu265. PubMed DOI PMC

Bannwarth S., Ait-El-Mkadem S., Chaussenot A., Genin E.C., Lacas-Gervais S., Fragaki K., Berg-Alonso L., Kageyama Y., Serre V., Moore D., et al. Reply: Two novel mutations in conserved codons indicate that CHCHD10 is a gene associated with motor neuron disease. Brain. 2014;137:e310. doi: 10.1093/brain/awu228. PubMed DOI PMC

Müller K., Andersen P.M., Hübers A., Marroquin N., Volk A.E., Danzer K.M., Meitinger T., Ludolph A.C., Strom T.M., Weishaupt J.H. Two novel mutations in conserved codons indicate that CHCHD10 is a gene associated with motor neuron disease. Brain. 2014;137:e309. doi: 10.1093/brain/awu227. PubMed DOI

Ajroud-Driss S., Fecto F., Ajroud K., Lalani I., Calvo S.E., Mootha V.K., Deng H.X., Siddique N., Tahmoush A.J., Heiman-Patterson T.D., et al. Mutation in the novel nuclear-encoded mitochondrial protein CHCHD10 in a family with autosomal dominant mitochondrial myopathy. Neurogenetics. 2015;16:1–9. doi: 10.1007/s10048-014-0421-1. PubMed DOI PMC

Penttilä S., Jokela M., Bouquin H., Saukkonen A.M., Toivanen J., Udd B. Late onset spinal motor neuronopathy is caused by mutation in CHCHD10. Ann. Neurol. 2015;77:163–172. doi: 10.1002/ana.24319. PubMed DOI

Watts G.D., Wymer J., Kovach M.J., Mehta S.G., Mumm S., Darvish D., Pestronk A., Whyte M.P., Kimonis V.E. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat. Genet. 2004;36:377–381. doi: 10.1038/ng1332. PubMed DOI

Senderek J., Garvey S.M., Krieger M., Guergueltcheva V., Urtizberea A., Roos A., Elbracht M., Stendel C., Tournev I., Mihailova V., et al. Autosomal-dominant distal myopathy associated with a recurrent missense mutation in the gene encoding the nuclear matrix protein, matrin 3. Am. J. Hum. Genet. 2009;84:511–518. doi: 10.1016/j.ajhg.2009.03.006. PubMed DOI PMC

Woo J.A., Liu T., Trotter C., Fang C.C., De Narvaez E., LePochat P., Maslar D., Bukhari A., Zhao X., Deonarine A., et al. Loss of function CHCHD10 mutations in cytoplasmic TDP-43 accumulation and synaptic integrity. Nat. Commun. 2017;8:15558. doi: 10.1038/ncomms15558. PubMed DOI PMC

Salton M., Elkon R., Borodina T., Davydov A., Yaspo M.-L., Halperin E., Shiloh Y. Matrin 3 binds and stabilizes mRNA. PLoS ONE. 2011;6:e23882. doi: 10.1371/journal.pone.0023882. PubMed DOI PMC

Coelho M.B., Attig J., Bellora N., König J., Hallegger M., Kayikci M., Eyras E., Ule J., Smith C.W. Nuclear matrix protein Matrin3 regulates alternative splicing and forms overlapping regulatory networks with PTB. EMBO J. 2015;34:653–668. doi: 10.15252/embj.201489852. PubMed DOI PMC

Borghero G., Pugliatti M., Marrosu F., Marrosu M.G., Murru M.R., Floris G., Cannas A., Parish L.D., Occhineri P., Cau T.B., et al. Genetic architecture of ALS in Sardinia. Neurobiol. Aging. 2014;35:2882. doi: 10.1016/j.neurobiolaging.2014.07.012. PubMed DOI PMC

Origone P., Verdiani S., Bandettini Di Poggio M., Zuccarino R., Vignolo M., Caponnetto C., Mandich P. A novel Arg147Trp MATR3 missense mutation in a slowly progressive ALS Italian patient. Amyotroph. Lateral Scler. Front. Degener. 2015;16:530–531. doi: 10.3109/21678421.2015.1058397. PubMed DOI

Lin K.P., Tsai P.C., Liao Y.C., Chen W.T., Tsai C.P., Soong B.W., Lee Y.C. Mutational analysis of MATR3 in Taiwanese patients with amyotrophic lateral sclerosis. Neurobiol. Aging. 2015;36:e1–e4. doi: 10.1016/j.neurobiolaging.2015.02.008. PubMed DOI

Jean-Philippe J., Paz S., Caputi M. hnRNP A1: The Swiss army knife of gene expression. Int. J. Mol. Sci. 2013;14:18999–19024. doi: 10.3390/ijms140918999. PubMed DOI PMC

Kim H.J., Kim N.C., Wang Y.D., Scarborough E.A., Moore J., Diaz Z., Diaz Z., MacLea K.S., Freibaum B., Li S., et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495:467–473. doi: 10.1038/nature11922. PubMed DOI PMC

Wall M.L., Lewis S.M. Methylarginines within the RGG-Motif Region of hnRNP A1 Affect Its IRES Trans-Acting Factor Activity and Are Required for hnRNP A1 Stress Granule Localization and Formation. J. Mol. Biol. 2017;429:295–307. doi: 10.1016/j.jmb.2016.12.011. PubMed DOI

Elvira G., Wasiak S., Blandford V., Tong X.K., Serrano A., Fan X., del Rayo Sánchez-Carbente M., Servant F., Bell A.W., Boismenu D., et al. Characterization of an RNA granule from developing brain. Mol. Cell Proteom. 2006;5:635–651. doi: 10.1074/mcp.M500255-MCP200. PubMed DOI

Guil S., Long J.C., Cáceres J.F. hnRNP A1 relocalization to the stress granules reflects a role in the stress response. Mol. Cell Biol. 2006;26:5744–5758. doi: 10.1128/MCB.00224-06. PubMed DOI PMC

Mc Donald K.K., Aulas A., Destroismaisons L., Pickles S., Beleac E., Camu W., Rouleau G.A., Vande Velde C. TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Hum. Mol. Genet. 2011;20:1400–1410. doi: 10.1093/hmg/ddr021. PubMed DOI

Taylor J.P. Multisystem proteinopathy: Intersecting genetics in muscle, bone, and brain degeneration. Neurology. 2015;85:658–660. doi: 10.1212/WNL.0000000000001862. PubMed DOI

Klar J., Sobol M., Melberg A., Mäbert K., Ameur A., Johansson A.C., Feuk L., Entesarian M., Orlén H., Casar-Borota O., et al. Welander distal myopathy caused by an ancient founder mutation in TIA1 associated with perturbed splicing. Hum. Mutat. 2013;34:572–577. PubMed

Brand P., Dyck P.J., Liu J., Berini S., Selcen D., Milone M. Distal myopathy with coexisting heterozygous TIA1 and MYH7 Variants. Neuromuscul. Disord. 2016;26:511–515. doi: 10.1016/j.nmd.2016.05.012. PubMed DOI

Hackman P., Sarparanta J., Lehtinen S., Vihola A., Evilä A., Jonson P.H., Luque H., Kere J., Screen M., Chinnery P.F., et al. Welander distal myopathy is caused by a mutation in the RNA-binding protein TIA1. Ann. Neurol. 2013;73:500–509. doi: 10.1002/ana.23831. PubMed DOI

Shalom O., Shalva N., Altschuler Y., Motro B. The mammalian Nek1 kinase is involved in primary cilium formation. FEBS Lett. 2008;582:1465–1470. doi: 10.1016/j.febslet.2008.03.036. PubMed DOI

Chen Y., Craigen W.J., Riley D.J. Nek1 regulates cell death and mitochondrial membrane permeability through phosphorylation of VDAC1. Cell Cycle. 2009;8:257–267. doi: 10.4161/cc.8.2.7551. PubMed DOI PMC

Pelegrini A.L., Moura D.J., Brenner B.L., Ledur P.F., Maques G.P., Henriques J.A., Saffi J., Lenz G. Nek1 silencing slows down DNA repair and blocks DNA damage-induced cell cycle arrest. Mutagenesis. 2010;25:447–454. doi: 10.1093/mutage/geq026. PubMed DOI

Fang X., Lin H., Wang X., Zuo Q., Qin J., Zhang P. The NEK1 interactor, C21ORF2, is required for efficient DNA damage repair. Acta Biochim. Biophys. Sin. 2015;47:834–841. doi: 10.1093/abbs/gmv076. PubMed DOI PMC

Van Rheenen W., Shatunov A., Dekker A.M., McLaughlin R.L., Diekstra F.P., Pulit S.L., van der Spek R.A., Võsa U., de Jong S., Robinson M.R., et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet. 2016;48:1043–1048. doi: 10.1038/ng.3622. PubMed DOI PMC

Nguyen H.P., Van Mossevelde S., Dillen L., De Bleecker J.L., Moisse M., Van Damme P., Van Broeckhoven C., van der Zee J., BELNEU Consortium NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients. Neurobiol. Aging. 2018;61:e1–e255. doi: 10.1016/j.neurobiolaging.2017.08.021. PubMed DOI

Chang J., Baloh R.H., Milbrandt J. The NIMA-family kinase Nek3 regulates microtubule acetylation in neurons. J. Cell Sci. 2009;122:2274–2282. doi: 10.1242/jcs.048975. PubMed DOI PMC

Helferich A.M., Brockmann S.J., Reinders J., Deshpande D., Holzmann K., Brenner D., Andersen P.M., Petri S., Thal D.R., Michaelis J., et al. Dysregulation of a novel miR-1825/TBCB/TUBA4A pathway in sporadic and familial ALS. Cell Mol. Life Sci. 2018;75:4301–4319. doi: 10.1007/s00018-018-2873-1. PubMed DOI PMC

Castellanos-Montiel M.J., Chaineau M., Durcan T.M. The Neglected Genes of ALS: Cytoskeletal Dynamics Impact Synaptic Degeneration in ALS. Front. Cell. Neurosci. 2020;14:594975. doi: 10.3389/fncel.2020.594975. PubMed DOI PMC

Wu C.H., Fallini C., Ticozzi N., Keagle P.J., Sapp P.C., Piotrowska K., Lowe P., Koppers M., McKenna-Yasek D., Baron D.M., et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature. 2012;488:499–503. doi: 10.1038/nature11280. PubMed DOI PMC

Wicks P., Abrahams S., Papps B., Al-Chalabi A., Shaw C.E., Leigh P.N., Goldstein L.H. SOD1 and cognitive dysfunction in familial amyotrophic lateral sclerosis. J. Neurol. 2009;256:234–241. doi: 10.1007/s00415-009-0078-0. PubMed DOI

Diekstra F.P., Van Vught P.W., Van Rheenen W., Koppers M., Pasterkamp R.J., Van Es M.A., Schelhaas H.J., de Visser M., Robberecht W., Van Damme P., et al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol. Aging. 2012;33:630. doi: 10.1016/j.neurobiolaging.2011.10.029. PubMed DOI

Sproviero W., Shatunov A., Stahl D., Shoai M., Van Rheenen W., Jones A.R., Al-Sarraj S., Andersen P.M., Bonini N.M., Conforti F.L., et al. ATXN2 trinucleotide repeat length correlates with risk of ALS. Neurobiol. Aging. 2017;51:e1–e178. doi: 10.1016/j.neurobiolaging.2016.11.010. PubMed DOI PMC

Lattante S., Pomponi M.G., Conte A., Marangi G., Bisogni G., Patanella A.K., Meleo E., Lunetta C., Riva N., Mosca L., et al. ATXN1 intermediate-length polyglutamine expansions are associated with amyotrophic lateral sclerosis. Neurobiol. Aging. 2018;64:e1–e157. doi: 10.1016/j.neurobiolaging.2017.11.011. PubMed DOI

Uyan Ö., Ömür Ö., Ağım Z.S., Özoğuz A., Li H., Parman Y., Deymeer F., Oflazer P., Koç F., Tan E., et al. Genome-wide copy number variation in sporadic amyotrophic lateral sclerosis in the Turkish population: Deletion of EPHA3 is a possible protective factor. PLoS ONE. 2013;8:72381. doi: 10.1371/journal.pone.0072381. PubMed DOI PMC

Morgan S., Shatunov A., Sproviero W., Jones A.R., Shoai M., Hughes D., Al Khleifat A., Malaspina A., Morrison K.E., Shaw P.J., et al. A comprehensive analysis of rare genetic variation in amyotrophic lateral sclerosis in the UK. Brain. 2017;140:1611–1618. doi: 10.1093/brain/awx082. PubMed DOI PMC

Cady J., Allred P., Bali T., Pestronk A., Goate A., Miller T.M., Mitra R.D., Ravits J., Harms M.B., Baloh R.H., et al. Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes. Ann. Neurol. 2015;77:100–113. doi: 10.1002/ana.24306. PubMed DOI PMC

Richards S., Aziz N., Bale S., Bick D., Das S., Gastier-Foster J., Grody W.W., Hegde M., Lyon E., Spector E., et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015;17:405–424. doi: 10.1038/gim.2015.30. PubMed DOI PMC

Nakamura R., Sone J., Atsuta N., Tohnai G., Watanabe H., Yokoi D., Nakatochi M., Watanabe H., Ito M., Senda J., et al. Next-generation sequencing of 28 ALS-related genes in a Japanese ALS cohort. Neurobiol. Aging. 2016;39:e1–e8. doi: 10.1016/j.neurobiolaging.2015.11.030. PubMed DOI

Mc Cann E.P., Henden L., Fifita J.A., Zhang K.Y., Grima N., Bauer D.C., Chan Moi Fat S., Twine N.A., Pamphlett R., Kiernan M.C., et al. Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis. J. Med. Genet. 2020;14:06866. PubMed

Vasilopoulou C., Morris A.P., Giannakopoulos G., Duguez S., Duddy W. What Can Machine Learning Approaches in Genomics Tell Us about the Molecular Basis of Amyotrophic Lateral Sclerosis? J. Pers. Med. 2020;10:247. doi: 10.3390/jpm10040247. PubMed DOI PMC

Tsuji S. Genetics of neurodegenerative diseases: Insights from high-throughput resequencing. Hum. Mol. Genet. 2010;19:R65–R70. doi: 10.1093/hmg/ddq162. PubMed DOI PMC

Riboldi G., Zanetta C., Ranieri M., Nizzardo M., Simone C., Magri F., Bresolin N., Comi G.P., Corti S. Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases. Mol. Neurobiol. 2014;50:721–732. doi: 10.1007/s12035-014-8724-7. PubMed DOI

Cappella M., Ciotti C., Cohen-Tannoudji M., Biferi M.G. Gene Therapy for ALS-A Perspective. Int. J. Mol. Sci. 2019;20:4388. doi: 10.3390/ijms20184388. PubMed DOI PMC